<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4578">
  <stage>Registered</stage>
  <submitdate>16/07/2014</submitdate>
  <approvaldate>16/07/2014</approvaldate>
  <nctid>NCT02195375</nctid>
  <trial_identification>
    <studytitle>Flutiform® Compared With Seretide® in the Treatment of COPD</studytitle>
    <scientifictitle>A Randomised Double-blind, Double-dummy Parallel Group Study to Compare the Efficacy and Safety of Fluticasone Propionate / Formoterol Fumarate (Flutiform®) 500/20 µg BID and 250/10 µg BID Versus Salmeterol / Fluticasone (Seretide®) 50/500 µg BID in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>FLT3510</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Flutiform 500/20 µg BID
Treatment: drugs - Flutiform 250/10 µg BID
Treatment: drugs - Seretide Accuhaler 50/500 µg BID

Experimental: Flutiform 500/20 µg BID - Flutiform 250/10 (2 puffs BID)

Experimental: Flutiform 250/10 µg BID - Flutiform 125/5 (2 puffs BID)

Active Comparator: Seretide Accuhaler 50/500 µg BID - Seretide Accuhaler 50/500 (BID)


Treatment: drugs: Flutiform 500/20 µg BID


Treatment: drugs: Flutiform 250/10 µg BID


Treatment: drugs: Seretide Accuhaler 50/500 µg BID


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Average pre-dose FEV1</outcome>
      <timepoint>26 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Average 1 hour Post dose FEV1, FVC, FEV6</outcome>
      <timepoint>26 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion:

          1. Male or Female subjects aged = 40 years at screening visit.

          2. Diagnosis of COPD

          3. Willing and able to replace current COPD therapy with study medication.

          4. Able to demonstrate correct use of a pMDI with or without a spacer and Accuhaler.

          5. Willing and able to attend all study visits and complete study assessments.

          6. Able to provide signed informed consent.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion:

          1. Ongoing moderate or severe exacerbation of COPD in the 2 weeks before screening.

          2. Current diagnosis of asthma.

          3. Documented evidence of a1-antitrypsin deficiency as the underlying cause of COPD.

          4. Other active respiratory disease such as active tuberculosis, lung cancer,
             bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung
             disease, cystic fibrosis, bronchiolitis obliterans.

          5. Previous lung resection.

          6. Use of long-term oxygen therapy (LTOT) or mechanical ventilation. Note: LTOT is
             defined as &gt;15 hours use per day

          7. Chest X-ray or CT scan that reveals evidence of clinically significant abnormalities
             not believed to be due to COPD.

          8. Evidence of uncontrolled cardiovascular disease.

          9. Evidence of clinically significant renal, hepatic, gastrointestinal, or psychiatric
             disease.

         10. Current malignancy or a previous history of cancer which has been in remission for &lt; 5
             years (basal cell or squamous cell carcinoma of the skin which has been resected is
             not excluded).

         11. Clinically significant sleep apnoea requiring use of continuous positive airway
             pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device.

         12. Participation in the acute phase of a pulmonary rehabilitation programme within 4
             weeks prior to screening or during the study.

         13. Known or suspected history of drug or alcohol abuse in the last 2 years.

         14. Requiring treatment with any of the prohibited concomitant medications.

         15. Known or suspected hypersensitivity to study drug or excipients.

         16. Received an investigational drug within 30 days of the screening visit (12 weeks if an
             oral or injectable steroid).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>923</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Fitzroy</hospital>
    <postcode> - Fitzroy</postcode>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Mundipharma Research Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to investigate whether flutiform® is effective and safe in the
      treatment of chronic obstructive pulmonary disease (COPD).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02195375</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>